PL2421520T3 - ALBUMINA i/lub MANNITOL DO LECZENIA POLIPÓW NOSA - Google Patents

ALBUMINA i/lub MANNITOL DO LECZENIA POLIPÓW NOSA

Info

Publication number
PL2421520T3
PL2421520T3 PL10717816T PL10717816T PL2421520T3 PL 2421520 T3 PL2421520 T3 PL 2421520T3 PL 10717816 T PL10717816 T PL 10717816T PL 10717816 T PL10717816 T PL 10717816T PL 2421520 T3 PL2421520 T3 PL 2421520T3
Authority
PL
Poland
Prior art keywords
mannitol
albumin
treatment
nasal polyposis
polyposis
Prior art date
Application number
PL10717816T
Other languages
English (en)
Inventor
Luigi Mercuri
Original Assignee
Dmg Italia Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dmg Italia Srl filed Critical Dmg Italia Srl
Publication of PL2421520T3 publication Critical patent/PL2421520T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38Albumins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
PL10717816T 2009-04-20 2010-04-19 ALBUMINA i/lub MANNITOL DO LECZENIA POLIPÓW NOSA PL2421520T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2009A000180A IT1399791B1 (it) 2009-04-20 2009-04-20 Composizioni farmaceutiche per il trattamento della poliposi nasale
PCT/IB2010/051703 WO2010122482A1 (en) 2009-04-20 2010-04-19 Pharmaceutical compositions for the treatment of nasal polyposis
EP10717816A EP2421520B1 (en) 2009-04-20 2010-04-19 Albumin and/or mannitol for the treatment of nasal polyposis

Publications (1)

Publication Number Publication Date
PL2421520T3 true PL2421520T3 (pl) 2013-06-28

Family

ID=41203922

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10717816T PL2421520T3 (pl) 2009-04-20 2010-04-19 ALBUMINA i/lub MANNITOL DO LECZENIA POLIPÓW NOSA

Country Status (9)

Country Link
EP (1) EP2421520B1 (pl)
DK (1) DK2421520T3 (pl)
ES (1) ES2402601T3 (pl)
IL (1) IL215854A (pl)
IT (1) IT1399791B1 (pl)
PL (1) PL2421520T3 (pl)
PT (1) PT2421520E (pl)
RS (1) RS52718B (pl)
WO (1) WO2010122482A1 (pl)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9149491B2 (en) 2013-04-29 2015-10-06 Harsha Chigurupati Reduced toxicity in alcoholic beverages

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1058612C (zh) * 1994-06-22 2000-11-22 刘廷栋 一种治疗鼻息肉的药膏
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
US8535707B2 (en) * 2006-07-10 2013-09-17 Intersect Ent, Inc. Devices and methods for delivering active agents to the osteomeatal complex
WO2009063367A1 (en) * 2007-11-15 2009-05-22 Pfizer Products Inc. Dosage forms comprising celecoxib providing both rapid and sustained pain relief

Also Published As

Publication number Publication date
EP2421520A1 (en) 2012-02-29
ES2402601T3 (es) 2013-05-07
PT2421520E (pt) 2013-04-15
RS52718B (sr) 2013-08-30
ITRM20090180A1 (it) 2010-10-21
IL215854A0 (en) 2012-01-31
WO2010122482A1 (en) 2010-10-28
IT1399791B1 (it) 2013-05-03
HK1165724A1 (en) 2012-10-12
DK2421520T3 (da) 2013-04-29
EP2421520B1 (en) 2013-01-16
IL215854A (en) 2014-11-30

Similar Documents

Publication Publication Date Title
GB2485291B (en) Cannabidiol for use in the treatment of generalised and/or partial seizures
IL213070A0 (en) Methods for the treatment of infections and tumors
IL210856A0 (en) Combination therapy for the treatment of diabetes and related conditions
IL217503A0 (en) Benzimidazole analogues for the treatment or prevention of flavivirus infections
ZA201204625B (en) Analogues for the treatment or prevention of flavivirus infections
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
ZA201202596B (en) Compounds for the treatment of dyslipidemia and related diseases
IL206563A0 (en) Medicament for the treatment of cancer of the pancreas
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
PL2763690T3 (pl) Liksysenatyd do stosowania w leczeniu stenozy i/lub niedrożności w układzie przewodów trzustkowych
ZA201001262B (en) Interval therapy for the treatment of tinnitus
EP2421553A4 (en) TISSUE KALLICREIN FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISORDER
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
ZA200908100B (en) Treatment and prevention of influenza
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
GB0714447D0 (en) Cannabidiol for use in the treatment of neurodegenerative conditions
IL200032A0 (en) Medicament for the treatment of endometriosis
IL216717A0 (en) USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES
PL2421520T3 (pl) ALBUMINA i/lub MANNITOL DO LECZENIA POLIPÓW NOSA
EP2467375A4 (en) FORMS OF DEXLANDSOPRAZOLE AND METHOD OF MANUFACTURING THEREOF
ZA200905300B (en) Medicament for the treatment of endometriosis
GB0909944D0 (en) Therapeutic agent and assay
GB0815179D0 (en) Medication and treatment for infection
AP3019A (en) Use of ferroquine in the treatment or prevention of malaria